



Know when to hold-em!  
Know when to fold-em!  
Know where to set stops!  
Know when to run!  
Never count your portfolio  
Until the sells are done..

[rhstruthers@gmail.com](mailto:rhstruthers@gmail.com)

519-374-9332

Monthly subscription US\$19.99

The Russel 2000, is officially in a bear market, down -21% and the NASDAQ is almost there, down -17.8%. Our Put options on Moderna and BioNTech moved quickly in our favour so some profits are a good idea.

Biotech investors are well aware that **the odds of any drug, vaccine or medical treatment making it all the way through clinical trials to market is very low.** The National Center for Biotechnology Information (NCBI) has been around for many decades and their expertise is biotech research. I wanted to put some numbers on this drug success rate. There [is a study at NCBI](#) that reveals that clinical success rates in advancing drugs to market between 2006 and 2015 found that only 9.6% of drugs entering phase I clinical testing will reach the market. **Since the Covid shots did not go through this process, it means that if so, the odds of having a safe and effective shot is only 1 in 10.**

That does not even include the ones that failed in animal trials, not even making phase 1 clinical trials. On that topic, this mRNA technology (called rDNA then to produce a spike protein) was [tried in a vaccine for Sars-cov-1 and in that case it never got past the animal trial level](#), but was tried on a few children never the less. Some quotes from the study -*"This effort was hampered by the occurrence in the initial preclinical trial of an immunopathogenic-type lung disease among ferrets and Cynomolgus monkeys given a whole virus vaccine adjuvanted with alum and challenged with infectious SARS-CoV."* They also tried it on some children and many got very sick and 2 died. *"The conclusion from that experience was clear; RSV lung disease was enhanced by the prior vaccination."*

They did not even do animal trials on the current shots.

*The reasons drugs/vaccines fail and don' get through the trials.*

- 50% of failures, because of previously unknown toxic side effects;
- 30% of failures, trials show insufficient efficacy;
- 15% of failures, commercial viability looks poor.

I believe another main reason these mRNA technology stocks are plummeting is both the CDC and WHO are changing their commentary/outlook on Covid-19 and the vaccines. I will show some of the CDC flip flop in another update, but the WHO was quite specific. **Repeating booster doses of the original COVID-19 vaccines is not a viable strategy against emerging variants**, the World Health Organization (WHO) said ["a vaccination strategy based on repeated booster doses of the original vaccine composition is unlikely to be appropriate or sustainable."](#)

**If you really want to understand vaccines, some of the history and how your immune system works with and without them, [this is an excellent read backed by numerous studies provided.](#) You will be surprised.**

Big charts is working today so I can show a comparison chart of Pfizer, Merck, Moderna and BioNTech. Note Pfizer is up about 20% in the last 6 months. Merck is even but Moderna and BioNTech are down -50% and more. The market is telling us that something is wrong with these mRNA stocks.



Moderna has hit and dropped below my \$150 target. We should sell, take profits on the Put Options



Name	Symbol	Buy Date	Buy Price	Current Price	Stop Loss	Gain %	12/31/20 Price	YTD Gain %	
MRNA	Mar 240 Put	Jan 22	57	97		70%	57	70%	sell 1/2
BNTX	Mar 200 Put	Jan 22	38	65		71%	38	71%	H

We are up 70% on the Moderna Put. I would at least sell 50% of your position or if you have both Puts, sell 100% because BioNTech has not met my \$125 target so will probably drop further.



Copyright 2022, Struther's Resource Stock Report

All forecasts and recommendations are based on opinion. Markets change direction with consensus beliefs, which may change at any time and without notice. The author/publisher of this publication has taken every precaution to provide the most accurate information possible. The information & data were obtained from sources believed to be reliable, but because the information & data source are beyond the author's control, no representation or guarantee is made that it is complete or accurate. The reader accepts information on the condition that errors or omissions shall not be made the basis for any claim, demand or cause for action. Because of the ever-changing nature of information & statistics the author/publisher strongly encourages the reader to communicate directly with the company and/or with their personal investment adviser to obtain up to date information. Past results are not necessarily indicative of future results. Any statements non-factual in nature constitute only current opinions, which are subject to change. The author/publisher may or may not have a position in the securities and/or options relating thereto, & may make purchases and/or sales of these securities relating thereto from time to time in the open market or otherwise. Neither the information, nor opinions expressed, shall be construed as a solicitation to buy or sell any stock, futures or options contract mentioned herein. The author/publisher of this letter is not a qualified financial adviser & is not acting as such in this publication.